InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)
InMed Pharmaceuticals' Gross Margin history spans 5 years, with the latest figure at 22.46% for Q4 2025.
- For Q4 2025, Gross Margin fell 1900.0% year-over-year to 22.46%; the TTM value through Dec 2025 reached 29.73%, down 566.0%, while the annual FY2025 figure was 34.53%, 1058.0% up from the prior year.
- Gross Margin reached 22.46% in Q4 2025 per INM's latest filing, down from 35.99% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 67.95% in Q2 2023 to a low of 153.07% in Q3 2022.
- Average Gross Margin over 5 years is 23.38%, with a median of 35.99% recorded in 2025.
- The largest YoY upside for Gross Margin was 15542bps in 2023 against a maximum downside of -4026bps in 2023.
- A 5-year view of Gross Margin shows it stood at 42.08% in 2021, then tumbled by -34bps to 27.92% in 2022, then dropped by -6bps to 26.14% in 2023, then skyrocketed by 59bps to 41.46% in 2024, then tumbled by -46bps to 22.46% in 2025.
- Per Business Quant, the three most recent readings for INM's Gross Margin are 22.46% (Q4 2025), 35.99% (Q3 2025), and 44.2% (Q2 2025).